Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

2004/06/01 by Anthony R. Mire‐Sluis, Anthony R Mire-Sluis, Yu Chen Barrett +17 · 31 citations
Medicine · Immunology and Microbiology · Biochemistry, Genetics and Molecular Biology · #Monoclonal and Polyclonal Antibodies Research #Biosimilars and Bioanalytical Methods #Biotin and Related Studies

paper · doi:10.1016/j.jim.2004.06.002

Cited by

• Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling
• An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug
• Affinity capture elution bridging assay: A novel immunoassay format for detection of anti-therapeutic protein antibodies
• Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
• Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics
• Integration of efficacy, pharmacokinetic and safety assessment of interleukin-1 receptor antagonist in a preclinical model of arthritis
• Critical ligand binding reagent preparation/selection: when specificity depends on reagents. [europepmc]
• Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. [europepmc]
• A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. [europepmc]
• Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). [europepmc]
• Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. [europepmc]
• A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. [europepmc]
• Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. [europepmc]
• Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. [europepmc]
• Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. [europepmc]
• Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. [europepmc]
• A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. [europepmc]
• Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team. [europepmc]
• Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. [europepmc]
• Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. [europepmc]
• Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. [europepmc]
• Assessing the Immunogenicity of Biopharmaceuticals. [europepmc]
• Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance. [europepmc]
• Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. [europepmc]
• Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. [europepmc]
• First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. [europepmc]
• Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies. [europepmc]
• T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020. [europepmc]
• Immunogenicity Risk Profile of Nanobodies. [europepmc]
• Anti-drug Antibody Validation Testing and Reporting Harmonization. [europepmc]
• Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies. [europepmc]